Tradestie Institutional Equity Comparison Engine

BNTX vs REGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BNTX counters with relative strength in Valuation. Fundamentally, BNTX trades at 7.0x Forward P/E with -55.5% operating margin (-15.1% YoY revenue) versus REGN at 14.9x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, BNTX sits in UNCLASSIFIED (76th %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BNTX
BNTX 7.0x vs REGN 14.9x Fwd P/E
Growth & Margin Winner REGN
Op Margin -55.5% vs 30.4% ยท YoY -15.1% vs +36.3%
Momentum & Technical Winner REGN
1Y -20.6% vs +27.3% ยท 52W Pos 4% vs 83%
Options & Structure Winner REGN
UNCLASSIFIED (76th %ile IV) vs CONSOLIDATION (6th %ile IV)
BNTX NASDAQ
BioNTech SE American Depositary Share
Biological Products, (No Diagnostic Substances)
$81.38
-2.26% 1D
Market Cap $20.6B
1M Return -10.86%
1Y Return -20.63%
Forward P/E 7.0x
Unified AI Score
43.3 / 100 HOLD
Tech 22.0 Fund 45.0 Flow 50.0 Mom 68.9
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BNTX -20.63% REGN +27.3% Spread: +47.93 pp (REGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BNTX TTM Op. Margin: -55.5% REGN TTM Op. Margin: 30.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BNTX vs REGN. Trailing 12-month operating profitability (BNTX -55.5% vs REGN 30.4%) and valuation multiples (BNTX 7.0x vs REGN 14.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BNTX (4) vs REGN (6)
Institutional Metric BNTX REGN Criterion Row Winner
Market Capitalization Scale $20.6B $97.8B Larger Scale REGN
Trailing P/E Ratio Valuation 7.0x 20.9x Lower Multiple BNTX
Forward P/E Ratio Valuation 7.0x 14.9x Lower Multiple BNTX
Revenue Growth (YoY) Growth -15.1% +36.3% Higher Growth REGN
Operating Margin (TTM) Profitability -55.5% 30.4% Higher Margin REGN
Net Profit Margin Profitability -60.9% 28.5% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency -8.1% 14.9% Higher ROE REGN
52-Week Range Position Momentum 4% ($80โ€“$124) 83% ($592โ€“$992) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.81ฮฒ ยท 31% Vol 0.32ฮฒ ยท 55% Vol Lower Realized Risk BNTX
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite BNTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BNTX vs REGN Buy Guide
BNTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 76th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live BNTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BNTX nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.